Victory in Bayer

As a result of our objection in the Bayer class action settlement, the parties modified the settlement to increase direct payments to the class by over $5.8 million, over 25 times as much as the class would have received in the cy pres-heavy settlement had we not objected. A second objection to one of the cy pres recipients resulted in a beneficiary more aligned with the purpose of the litigation. The district court has not yet finalized its decision on the fees to be awarded to plaintiffs' counsel. We'll be seeking modest attorneys' fees to come out of class counsel's share; if we are awarded more than $50,000 (less than 1% of the additional benefit to class members), we'll cede the rest to the settlement fund.

In re Bayer

Fewer than 20,000 class members have bothered to go through the arduous claim procedures in the Bayer Corp. class action, which caps recovery for most of those class members at $4 unless they saved several-year-old receipts for aspirin products. The class will ultimately receive well under $500,000.

But the attorneys—led by Hagens Berman—are asking for $5.1 million for themselves. The fee is supposedly justified because about $8-$9 million will end up in the hands of cy pres recipients such as the American Heart Association. Of course, Bayer already gives money to the AHA (and the AHA returns the favor by endorsing Bayer aspirin over other brands of aspirin), so this is really just a change in accounting entries rather than any sort of class benefit.

I'm a class member and I have objected through my attorney Adam Schulman of the Center for Class Action Fairness. The case is In re Bayer Corp. Combination Aspirin Prods. Mktg. & Sales Pract. Lit., No. 09-md-2023 (BMC) (E.D.N.Y.).